tetano
Editor, Senior Moderator
Br J Haematol
. 2022 Nov 16.
doi: 10.1111/bjh.18562. Online ahead of print.
Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation
Andriyana K Bankova[SUP] 1 [/SUP], Chloé Pasin[SUP] 2 3 [/SUP], Alice Huang[SUP] 1 [/SUP], Caroline Cicin-Sain[SUP] 1 [/SUP], Selina Epp[SUP] 2 [/SUP], Annette Audige[SUP] 2 [/SUP], Nicolas J Mueller[SUP] 3 [/SUP], Jakob Nilsson[SUP] 4 [/SUP], Oliver Vilinovszki[SUP] 1 5 [/SUP], Gayathri Nair[SUP] 1 [/SUP], Nathan Wolfensberger[SUP] 1 [/SUP], Philipp Hockl[SUP] 1 [/SUP], Urs Schanz[SUP] 1 [/SUP], Alexandra Trkola[SUP] 2 [/SUP], Roger Kouyos[SUP] 2 3 [/SUP], Barbara Hasse[SUP] 3 [/SUP], Annelies S Zinkernagel[SUP] 3 [/SUP], Markus G Manz[SUP] 1 [/SUP], Irene A Abela[SUP] 2 3 [/SUP], Antonia M S Müller[SUP] 1 6 [/SUP]
Affiliations
Abstract
Allogeneic haematopoietic cell transplantation (allo-HCT) recipients show impaired antibody (Ab) response to a standard two-dose vaccination against severe acute respiratory syndrome coronavirus-2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo-HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo-HCT recipients is critical to optimise current vaccination strategies.
Keywords: allogeneic haematopoietic cell transplantation; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); vaccine response.
. 2022 Nov 16.
doi: 10.1111/bjh.18562. Online ahead of print.
Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation
Andriyana K Bankova[SUP] 1 [/SUP], Chloé Pasin[SUP] 2 3 [/SUP], Alice Huang[SUP] 1 [/SUP], Caroline Cicin-Sain[SUP] 1 [/SUP], Selina Epp[SUP] 2 [/SUP], Annette Audige[SUP] 2 [/SUP], Nicolas J Mueller[SUP] 3 [/SUP], Jakob Nilsson[SUP] 4 [/SUP], Oliver Vilinovszki[SUP] 1 5 [/SUP], Gayathri Nair[SUP] 1 [/SUP], Nathan Wolfensberger[SUP] 1 [/SUP], Philipp Hockl[SUP] 1 [/SUP], Urs Schanz[SUP] 1 [/SUP], Alexandra Trkola[SUP] 2 [/SUP], Roger Kouyos[SUP] 2 3 [/SUP], Barbara Hasse[SUP] 3 [/SUP], Annelies S Zinkernagel[SUP] 3 [/SUP], Markus G Manz[SUP] 1 [/SUP], Irene A Abela[SUP] 2 3 [/SUP], Antonia M S Müller[SUP] 1 6 [/SUP]
Affiliations
- PMID: 36382698
- DOI: 10.1111/bjh.18562
Abstract
Allogeneic haematopoietic cell transplantation (allo-HCT) recipients show impaired antibody (Ab) response to a standard two-dose vaccination against severe acute respiratory syndrome coronavirus-2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo-HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo-HCT recipients is critical to optimise current vaccination strategies.
Keywords: allogeneic haematopoietic cell transplantation; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); vaccine response.